A simple test for the high-frequency P291fsinsC mutation in the HNF1a/MODY3 gene Dear Sir, Maturity-onset diabetes of the young (MODY) is a genetically heterogeneous form of diabetes characterised by autosomal dominant inheritance, onset usually before the age of 25 and beta-cell dysfunction. The most common subtype in many populations seems to be MODY3 which is caused by mutations in the gene encoding hepatocyte nuclear factor (HNF)-1a. A mutation in exon 4 of HNF1a, namely P291fsinsC, is particularly prevalent among Caucasian patients. The nature of this MODY3 hot spot mutation is an insertion of an extra cytosine into a polycytidine tract consisting of eight residues, and it leads to a truncated protein which can act in a dominant-negative manner [1] . In materials of suspected MODY families, 30±70 % have been reported to possess mutations in the HNF1a gene [2±4]. P291fsinsC has been observed to occur in as many as 50 % of identified MODY3 families [4] but a proportion of 20±30 % seems more likely [1±3] . In a study of 60 MODY probands defined by strict criteria, eight P291fsinsC-positive subjects were found [5] . Thus, 10±15 % of all suspected MODY patients might bear this particular mutation.
When starting an investigation on the genetic epidemiology of MODY in Norway, we therefore found it reasonable first to screen suspected MODY families for P291fsinsC. The only published test specifically aiming at identifying P291fsinsC [5] is based on measuring size of a fluorescently labelled PCR product on an automated DNA sequencer. We decided to design a restriction enzyme-based test that would be simpler in use.
The insertion of a cytosine in codon 291 neither deletes an existing restriction site nor creates a new one. When designing the test, we therefore introduced an ªartificialº restriction enzyme site by a mismatch (underlined) in the forward primer, 5¢ -CATGGACACGTACAGCGG(G/C)CCCCC-CTC-3¢; thereby creating a Bsu36I site only for non-mutated subjects. To take into account the G-to-C polymorphism in codon 288 [2] , the forward primer was a 1:1 mixture of two primers with G or C as the 19th base. As reverse primer we selected 5¢-CCTCCCCAACCCTCCCACCTTAGGACGTGTCC-CTTG-3¢, where the mismatch (underlined) always introduces a Bsu36I site serving as an internal control for restriction enzyme function. The size of the PCR product from the normal allele is 164 base pairs (bp) and digestion with Bsu36I yields fragments of 117 bp, 25 bp and 22 bp. The product size from the P291fsinsC allele is 165 bp and Bsu36I digestion gives rise to fragments of 143 bp and 22 bp.
We first carried out PCR amplifications with a standard PCR enzyme (AmpliTaq DNA polymerase; PE Corporation, Norwalk, Conn., USA) under conditions recommended by the manufacturer. We observed, however, an unexpected result as the restriction enzyme digest identified all normal subjects as heterozygotes for the mutation. It is well known that there is a tendency for DNA polymerases to introduce single-base deletions or additions when replicating stretches of iterated nucleotides. The rate of frame-shifting increases with the number of repeated nucleotides, and the postulated mechanism is misalignment of the growing DNA strand during replication (DNA slippage) [6] . This phenomenon could itself be the molecular basis for the relatively high frequency of P291fsinsC.
We therefore assumed that the AmpliTaq polymerase encountered fidelity problems when it amplified the hot spot area, resulting in frame-shifting and a partial loss of the Bsu36I site also in the PCR product from normal subjects. Of four other commercially available DNA polymerases that were tested, a modified version of Taq polymerase (SuperTaq; HT Biotechnology, Cambridge, UK) had the best ability to discern between normal and P291fsinsC alleles. The PCR amplification was done in a Perkin Elmer 2400 thermoycler using 0.15 U of SuperTaq and 200 ng genomic DNA per 50 ml reaction. The reaction mix consisted of 1 mmol/l of each primer, 200 mmol/l of each deoxyribonucleoside triphosphate (dNTP), 10 mmol/l TRIS-HCl (pH 9.0), 1.5 mmol/MgCl 2 , 50 mmol/ KCl and 0.1 % Triton X-100. An initial denaturation step at 94°C for 2 min was followed by 35 cycles of 94°C for 30 s, 57°C for 30 s and 72°C for 1 min, and a final incubation at 72°C for 7 min.
The P291fsinsC mutation is the disease-causing mutation of N1, the first registered MODY family in Norway [7, 8] . It was originally found by sequencing and we re-examined DNA samples from family N1 with the restriction enzyme-based test. A part of the N1 pedigree with the corresponding restriction pattern is shown in Figure 1 . The test was further evaluated by screening DNA from twelve unrelated MODY3 patients with or without the hot spot mutation and with or without the G-to-C polymorphism in codon 288. Ten samples were from the University of Chicago and two samples were kindly provid-ed by Dr. S. Menzel, University of Oxford, England. The test correctly identified the six mutated alleles in the twelve samples with no false negatives or positives. We further screened our current material of 19 Norwegian MODY probands for the hot spot mutation. Including N1, three families were positive, indicating a prevalence in Norway of P291fsinsC similar to that observed in other populations [2, 3, 5] .
In conclusion, we believe that the test presented here is well suited for pre-screening larger patient materials of Caucasian origin for the MODY3 insertion mutation in codon 291. Because of the inherent difficulty in replicating the hot spot region with high fidelity, the choice of DNA polymerase and cycling/buffer conditions is, however, crucial for a successful test. Finally, it should be noted that the heterozygous restriction pattern shown in Figure 1 A simple test for the high-frequency P291fsinsC mutation of the HNF1a gene. The pedigree is part of a Norwegian MODY3 family reported previously [7, 8] . Patients with verified Type II (non-insulin-dependent) diabetes mellitus are indicated by black symbols. Open symbols denote non-diabetic subjects. The P291fsinsC mutation is identified by an extra band of 143 bp on the agarose gel (patients 19, 20 and 25). Lane M: FX174 DNA cut with HaeIII (size marker). Lane U: uncut PCR product
